Michael P. Bailey

Michael P. Bailey (chief executive) discloses dealings in 4 companies, chiefly Aveo Pharmaceuticals, Inc., Imclone Systems Inc/de and Madrigal Pharmaceuticals, Inc. Over a trading history stretching from 12 July 2007 to 21 May 2026, the count stands at 31 filings.

Both buying and selling appear: 2 purchases worth €163k, against 7 sales worth €707k. On balance, insiders were net sellers of €544k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 9 share grants and 8 option exercises.

The latest filing, published on 27 May 2026, reports a share grant in Verastem, Inc. The latest purchase dates back some time: it was published 1,877 days ago, on 3 September 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.